ArticlePituitary2026
Absence of detectable circadian rhythmicity of neurophysin I, a surrogate marker for oxytocin.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOxytocin (OXT) plays key roles in social behaviour, stress regulation, and reproductive physiology. OXT deficiency has been described in pituitary disorders and is associated with increased anxiety and impaired prosocial behaviour. Despite growing clinical interest, the circadian regulation of OXT remains poorly defined, largely due to methodological limitations in measuring endogenous OXT. Neurophysin I (NP-I), a stable carrier protein co-released with OXT, represents a reliable surrogate marker. Characterizing the circadian profile of NP-I may therefore provide important insights into oxytocinergic function with implications for diagnostics and future replacement strategies.
methodsThis study is a secondary analysis of a prospective, observational trial conducted in healthy adults under highly standardized conditions. Thirteen participants underwent hourly blood sampling over 24 h following overnight fasting, controlled fluid intake, standardized meals, and regulated light exposure and physical activity. All assessments were performed on the clinical research ward to minimize external influences on hormone secretion.
resultsThirteen healthy participants (median age 23 years [IQR, 19–24]; 46% female; BMI 22.8 ± 1.6 kg/m²) underwent 24-hour hormone profiling. NP-I concentrations ranged from 50 to 8,607 pg/mL. The overall median NP-I concentration was 822 pg/mL [339–1,392], with a mean of 1,609 pg/mL (2,084). Individual median 24-hour NP-I concentrations ranged from 143 pg/mL [114–186] to 7,103 pg/mL [6,380–7,714]. Across participants, NP-I levels peaked at approximately 05:30 and reached a nadir at approximately 16:30. The estimated oscillation amplitude was small (35 pg/mL) and not statistically significant (95% CI −110 to 181; p > 0.05), indicating the absence of a robust population-level circadian rhythm. Female participants exhibited higher NP-I concentrations than males (median 1,372 pg/mL [468–5,344] vs. 687 pg/mL [297–932]), with markedly elevated levels—approximately four- to five-fold higher—in two women using hormonal contraception.
conclusionUnder resting, unstimulated conditions, circulating NP-I levels in healthy adults do not display significant circadian rhythmicity, suggesting stable basal oxytocinergic output. Exploratory findings indicate potential sex-related differences that warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.